Idenix/Novartis Telbivudine NDA Filing Slated For Late 2005, IPO Says
Executive Summary
Idenix plans to file an NDA for the hepatitis B therapy telbivudine in late 2005, the Cambridge-based biotech company says in an initial public offering filed with the Securities & Exchange Commission Dec. 15